April milk prices confirmed by co-ops
Dairygold has maintained the April quoted milk price at 50cpl, based on standard constituents of 3.3% protein and 3.6% butterfat, inclusive of sustainability and quality payments and VAT.
This price equates to an average of 54.6cpl farm gate milk price based on the average solids achieved in April by milk suppliers. The quoted price for April was based on EU Standard constituents of 3.4% protein and 4.2% butterfat, and is 54.5cpl, inclusive of VAT.
A spokesperson for Dairygold commented that 'global milk production continues to be relatively steady, but buyers remain cautious amid the threat of tariffs… Butter prices have maintained their strong price levels, although other dairy products have been less robust.'
Carbery has maintained its milk price for the month of April. If this is carried across the four West Cork co-ops, Bandon, Barryroe, Drinagh, and Lisavaird, this will result in an average milk price of 52.12cpl, inclusive of VAT, 0.5cpl somatic cell count (SCC) bonus, and the FutureProof sustainability bonus.
The base milk price adjustment for SCC and the FutureProof bonus figures are quoted excluding VAT. The total FutureProof bonus available in 2025 is 1.25cpl, an increase of 0.25cpl.
Similarly to the Dairygold spokesperson regarding uncertainty of tariffs, Carbery have said "wider uncertainty around the outlook for global markets in the face of potential tariffs is somewhat impacting dairy market performance'.
Tirlán will pay a total of 50.08cpl, including VAT, for April milk supplies at 3.6% butterfat and 3.3% protein. The April milk price consists of the base milk price of 49.58 cpl (including VAT), which is unchanged from March, and the sustainability action payment of 0.5 cpl (including VAT) to all qualifying suppliers.
Both payments will be adjusted based on the actual constituents of milk delivered by farmers. The actual average price paid by Tirlán for April creamery milk, based on delivered constituents, will be 54.99 cpl (including VAT).
Tirlán chairperson, John Murphy, said: 'While dairy markets are relatively stable, there has been a decline in returns for some individual products. We are pleased to be able to maintain farm gate milk price at over 50 cent per litre for the high-volume month of April.
"The outcome of trade discussions over the coming period is likely to impact market direction. Consumer reaction to higher prices will also need to be closely watched.'
Lakeland Dairies has also left the price of milk unchanged for milk supplied in April.
The base price of 48.75cpl for constituents of 3.6% butterfat and 3.3% protein, a retention of last month's price. This price is inclusive of the 0.5cpl sustainability incentive payment.
Lakeland Dairies has said that although there are geopolitical tensions and uncertainty surrounding the economic performance of dairy, the supply-demand dynamic remains largely in balance, which is providing market stability.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Examiner
07-08-2025
- Irish Examiner
Eli Lilly shares drop after weight-loss 'wonder drug' disappoints
Eli Lilly shares fell as disappointing data on its new weight-loss pill overshadowed strong growth from the company's current obesity medicine, which helped drive it to raise its yearly profit and sales outlook. Lilly's results from an obesity pill study, a drug key to unlocking billions of dollars of growth, didn't perform as well as Wall Street expected. It resulted in lower weight loss and higher rates of nausea and vomiting, side-effects associated with so-called GLP-1 drugs. The data was a boon for rival Novo Nordisk. 'There was hope that this would be a wonder drug,' BMO analyst Evan Seigerman said of Lilly's pill. 'What this shows to me is that it's still a good drug, but it's bound by the limitations of being a GLP-1.' Novo rose as much as 14.3% in Copenhagen, the most in almost four months. Drugmakers are in a hotly contested race to dominate the market for obesity medications. Lilly had moved into pole position against Novo thanks to Zepbound, its powerful injectable drug, but Lilly's sky-high valuation is tied in part to eventually turning its weight-loss pill into a blockbuster. Eli Lilly has major operations in Ireland with facilities in Kinsale, Little Island and Limerick. Investors say pills are a vital part of reaching more patients in the market that's expected to grow to $95bn (€82.2bn) by 2030. But the science has proved to be a challenge. Pfizer and AstraZeneca are among a handful of companies that have faced setbacks as they race to develop potent pills of their own. In Lilly's pill study, patients on the highest dose shed roughly 11% of their body weight, or 25 pounds, the company said. In late-stage trials, patients on Novo's injectable Wegovy lost about 15% of their weight over a 68-week period. The most common side-effects were nausea, vomiting and diarrhoea, which occurred at rates similar to existing GLP-1 drugs, Lilly said in a statement detailing the results. Notably, the medication didn't cause liver issues, a concern with other weight-loss pills in development. About 10% of patients dropped out of the study due to side-effects. Competition Lilly's data raises doubts over whether the pill, called orforglipron, can meet Wall Street's estimates of $12bn (€10.4bn) in annual sales by 2030, Bloomberg Intelligence analysts John Murphy and Christos Nikoletopoulos wrote. The company plans to submit the findings from the 18-month study involving more than 3,100 adults to regulatory agencies for approval by the end of the year. Detailed results will be presented at a medical conference in September. If approved, Lilly's once-daily pill would likely hit pharmacy shelves next year. Orforglipron is easier to manufacture than its current injectable Zepbound and is expected to be a cheaper option for patients. Novo has filed an oral version of its weight-loss blockbuster Wegovy for US approval, but it's more complicated to produce than Lilly's and will likely have more dosing restrictions, such as when patients can eat and drink. For investors, it has been a further example of Novo slipping behind after its next-generation obesity drug, CagriSema, also fell short of expectations in clinical trials. But Lilly's result offered Novo a welcome narrative shift on the same day that Maziar Mike Doustdar takes over as CEO from Lars Fruergaard Jorgensen. Eli Lilly sales forecast On Thursday, Lilly also increased its sales projections for the year and now expects revenue between $60 billion and $62 billion, up from a range of $58 billion to $61 billion. The company said in a statement it expects 2025 profit to reach $21.75 to $23 a share, up from $20.78 to $22.28. Lilly's second-quarter sales were $15.6 billion, beating analysts' average estimates of $14.7 billion. Zepbound surpassed expectations, while the diabetes medicine Mounjaro beat the Street's view. Adjusted profits were $6.29 per share, which outpaced analysts' $5.57 per share expectation.
RTÉ News
07-08-2025
- RTÉ News
Tirlán starts work on solar farm to power largest production facility
Food company Tirlán, formerly Glanbia Co-Op, has started work on a major renewable energy project at its multi-purpose integrated dairy processing facility in Ballyragget, Co Kilkenny which will reduce the site's carbon footprint and its reliance on grid electricity. The 6.5 hectare, 8 MWp ground-mounted solar farm is being delivered in partnership with ESB's Smart Energy Services. It is expected to be completed in early 2026. Tirlán said the new solar farm will be a "behind-the-meter" self-generation project, meaning all energy produced will be consumed directly at the Ballyragget facility. Once operational, it will supply approximately 7.6 GWh of clean renewable energy a year, meeting 34% of the site's imported electricity needs. That is the equivalent of powering over 1,700 households with electricity for a year, the company said. The solar array will consist of 12,816 photovoltaic panels and 32 inverters and is expected to reduce the carbon footprint by 2,100 tonnes of CO₂ annually. This is roughly equivalent to removing 450 diesel cars from Irish roads or planting 94,000 evergreen trees. Over its 25-year lifespan, the project will avoid about 50,000 tonnes of CO₂. The Ballyragget processing facility is one of the largest multi-purpose integrated dairy plants in Europe. The site employs over 360 people, processing up to 1.2 billion litres of milk, 1.3 billion litres of whey and up to 200 million litres of cream annually. Over €180m has been invested during the last decade in developing and enhancing the site, which has been operational for more than 50 years. Tirlán's Chairperson John Murphy said the investment is a key milestone in the company's journey to further decarbonise its operations and strengthen energy resilience at its largest processing site. "It builds on the success of solar installations at our Kilkenny Soup Plant and Tirlán CountryLife Castlecomer retail branch and reflects our commitment to a more sustainable energy mix," Mr Murphy said. "In addition, there has been a strong uptake of 'turn-key' solar packages on-farm to help suppliers reduce both their carbon emissions and cost through our FarmGen programme," he added. Ciaran Gallagher, Head of Smart Energy Services at ESB, said that by enabling projects like this solar farm in Ballyragget to generate clean electricity, the company is helping to reduce emissions and enhance energy resilience at scale. "This project is a shining example of how Irish industry can lead the way in renewable energy innovation. We're committed to supporting Tirlán in delivering a future-focused solution that not only cuts carbon emissions but also strengthens operational sustainability," he added.
Agriland
06-08-2025
- Agriland
Ornua products see wins at international dairy competition
Irish dairy product producer Ornua, which makes the Kerrygold butter brand, has seen a number of wins at an international competition for cheese and dairy products. The International Cheese and Dairy Awards, which took place in Staffordshire in England, featured some 3,750 entries from various countries. According to Ornua, the competition is the world's largest cheese and dairy competition, and was judged by "leading international industry experts". The Irish dairy business said it won 23 awards in total, including four "major trophies", six gold awards, six silver awards, and seven bronze awards. Ornua's Vintage Cheddar, made by Tirlán at its Ballyragget plant in Co. Kilkenny, won the DSM Trophy for the Best Single Vintage Creamery/Block Cheddar. Other awards were presented to Ornua for cheese supplied by Carbery, Dairygold and Tirlán's plant in Co. Wexford. Ornua said these wins "demonstrate the range and supreme quality of Irish cheese and expertise of Ornua's member co-ops". The business' Pilgrims Choice cheddar brand - the second-most popular cheddar brand in the UK according to Ornua - won seven awards, including three gold awards, three silver awards, and one bronze award. It also won three "major trophies" for its Extra Mature Cheddar. These awards were for Reserve Champion Overseas, Champion Overseas Cheddar, and Best Irish Cheddar. The Pilgrims Choice "Inclusions" range won a number of awards for its blended chesses, including in the Best Additive Cheese category, in which three different products from the range won the gold, silver and bronze awards. Apart from the award wins for cheese products, Ornua's flagship product, Kerrygold, won five awards. Kerrygold Unsalted Butter received a gold award, while the 'Sweet Spreadable' range won a number of awards, including two silver awards for on product in the dairy/butter spread category and the flavoured butter category. Another Kerrygold 'Sweet Spreadable' product won two bronze medals, also in the dairy/butter spread and flavoured butter category.
